Workup for Elevated High-Sensitivity C-Reactive Protein
When you find an elevated hs-CRP, first repeat the measurement in 2 weeks (fasting or non-fasting) and average the two results; if hs-CRP remains ≥10 mg/L after repeat testing, evaluate for non-cardiovascular causes of infection or inflammation. 1, 2
Initial Assessment and Repeat Testing
- Obtain two hs-CRP measurements optimally 2 weeks apart and average the results to account for biological variability and ensure metabolically stable conditions 2
- Both measurements can be fasting or non-fasting 2
- If either measurement shows hs-CRP ≥10 mg/L, this triggers a different workup pathway (see below) 1, 2
Risk Stratification Based on hs-CRP Levels
After obtaining averaged measurements, categorize cardiovascular risk:
- Low risk: <1.0 mg/L 2, 3
- Average risk: 1.0-3.0 mg/L 2, 3
- High risk: >3.0 mg/L (associated with 2-fold increased cardiovascular risk) 2, 3, 4
Workup for Markedly Elevated hs-CRP (≥10 mg/L)
Persistently elevated hs-CRP ≥10 mg/L after repeat testing requires evaluation for non-cardiovascular inflammatory or infectious causes. 1, 2
Search specifically for:
- Bacterial infections (account for 88% of extreme CRP elevations, with mortality reaching 36% overall and 61% in patients with active malignancies) 5
- Inflammatory bowel disease 2
- Rheumatoid arthritis 2
- Active malignancies (particularly important given high mortality) 5
- Long-term alcoholism 2
- Other systemic inflammatory or infectious processes 6
Cardiovascular Risk Assessment for Moderate Elevations
For hs-CRP levels 1-10 mg/L, the workup focuses on cardiovascular risk stratification:
- Calculate 10-year cardiovascular risk using Framingham or pooled cohort equations 3
- hs-CRP is most useful in intermediate-risk patients (10-20% 10-year CHD risk) where it may guide decisions about initiating or intensifying therapy 1, 3
- In intermediate-risk patients with hs-CRP ≥2 mg/L, reclassify them to higher risk warranting more aggressive intervention including statin therapy 3
Who Should Have hs-CRP Measured
Measure hs-CRP selectively in:
- Asymptomatic adults with intermediate cardiovascular risk (10-20% 10-year ASCVD risk) when the result would influence decisions about statin therapy 3
- Men ≥50 years or women ≥60 years with LDL cholesterol <130 mg/dL who are not on lipid-lowering therapy, hormone replacement, or immunosuppressants 3
- Exclude patients with clinical CHD, diabetes, chronic kidney disease, severe inflammatory conditions, or statin contraindications 3
Treatment Implications
Do not treat hs-CRP as an isolated target; focus on comprehensive cardiovascular risk reduction. 1, 3
- Statin therapy reduces hs-CRP levels (though response is heterogeneous), and patients with elevated hs-CRP may derive greater absolute risk reduction from statins 3, 7
- Aspirin may provide greater benefit in patients with elevated hs-CRP based on post-hoc analyses from the Physicians' Health Study 3
- Address all modifiable risk factors: blood pressure, glucose control, weight management 3
Critical Pitfalls to Avoid
- Never use serial hs-CRP testing to monitor treatment effects (Class III recommendation) 1, 3
- Do not base acute coronary syndrome management on hs-CRP levels (Class III recommendation) 1, 3
- Secondary prevention measures should not depend on hs-CRP determination (Class III recommendation) 1
- Do not measure hs-CRP during acute illness or active inflammation, as it loses cardiovascular predictive value 2
- Recognize that hs-CRP is not specific for atherosclerosis and cannot be interpreted in the setting of other systemic inflammatory or infectious processes 6